Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2023 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE, Mass., May 04, 2023 (GLOBE...
May 02, 2023 07:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Acquisition includes Exacis’ entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc....
April 11, 2023 08:00 ET | Source: Eterna Therapeutics

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
March 28, 2023 08:30 ET | Source: Eterna Therapeutics

Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna as it advances its mRNA cell engineering platform ...
March 20, 2023 16:10 ET | Source: Eterna Therapeutics

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications –...
February 22, 2023 08:00 ET | Source: Eterna Therapeutics

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell...
January 04, 2023 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to...
November 01, 2022 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop...
October 18, 2022 08:30 ET | Source: Eterna Therapeutics Inc.

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop...
October 17, 2022 08:30 ET | Source: Eterna Therapeutics Inc.

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Exacis’ iNK and iT cells, made using non-viral, episome-free cell...